You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma

 

Online download statistics by month:

Online download statistics by month: June 2022 to February 2026

AbstractFullPdf
Jun 2022478495170
Jul 2022212217174
Aug 202220020085
Sep 202231532178
Oct 202214714842
Nov 202218718746
Dec 202210910917
Jan 2023848430
Feb 2023858736
Mar 2023434326
Apr 2023626225
May 2023535433
Jun 2023545435
Jul 2023343413
Aug 2023545526
Sep 2023515115
Oct 2023515130
Nov 2023494924
Dec 2023484932
Jan 2024464730
Feb 2024424218
Mar 2024949531
Apr 2024797945
May 2024615932
Jun 2024737127
Jul 2024626226
Aug 2024636238
Sep 2024656532
Oct 2024717331
Nov 202410010349
Dec 202417317647
Jan 2025868624
Feb 202524324331
Mar 2025828247
Apr 202512012040
May 202511611555
Jun 2025949435
Jul 2025110
Feb 2026100
Total398840251575